Licenciamento voluntário de patentes e acesso a medicamentos: o caso do sofosbuvir

• Autor(a) principal: Chein Feres, Marcos Vinício
• Data de Publicação: 2020
• Outros Autores: da Silva Sant'Anna, Leonardo, Silva, Alan Rossi
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Justiça do Direito (Online)
• Texto Completo: http://seer.upf.br/index.php/rjd/article/view/10138

This paper aims to investigate empirically whether voluntary licensing of sofosbuvir can be considered an appropriate strategy for expanding access to this medicine. This research was carried out stemming from a holistic, descriptive, single-case study on the subject, according to the definitions elaborated by Robert Yin and the theoretical propositions formulated by Susan Sell. As a main result, it was possible to infer that voluntary licensing does not appear to be a strategy capable of effectively increasing access to sofosbuvir, and may even have the opposite effect by limiting competition and, thus, maximizing the licensor's patent exclusivity. Moreover, it was also possible to conclude that, in any case, this strategy cannot be considered automatically adequate for expanding access to patent protected medicines.